CoChat
Sign Up
Cited by 246

The DOI matches its Crossref record.

Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro

Rao, Quan, Zuo, Bingfeng, Lu, Zhen, Gao, Xianjun, You, Abin, Wu, Chenxuan, Du, Zhi, Yin, HaiFang·2016·Hepatology
DOI 10.1002/hep.28549
Open this paper in CoChat — free account

Abstract

Hepatocellular carcinoma (HCC) remains a global challenge due to high morbidity and mortality rates and poor response to treatment. Immunotherapy, based on introduction of dendritic cells (DCs) activated by tumor cell lysates as antigens ex vivo, shows limited response rates in HCC patients. Here, we demonstrate that tumor cell–derived exosomes (TEXs), displaying an array of HCC antigens, can elicit a stronger immune response than cell lysates in vitro and in vivo. Significant tumor growth inhibition was achieved in ectopic and orthotopic HCC mice treated with TEX‐pulsed DCs. Importantly, the tumor immune microenvironment was significantly improved in orthotopic HCC mice treated by TEX‐pulsed DCs, demonstrated by increased numbers of T lymphocytes, elevated levels of interferon‐γ, and decreased levels of interleukin‐10 and tumor growth factor‐β in tumor sites. As expected, T cells played an essential role in the TEX‐pulsed DC‐mediated immune response. Notably, exosomes from HCC cells not only promoted HCC‐specific cytolysis but also provided cross‐protective effects against pancreatic cancer cells. Moreover, HCC‐specific cytolysis, elicited by DCs pulsed with human HepG2 cell–derived exosomes, was observed across different human HCC cells irrespective of human leukocyte antigen types. Conclusion: HCC TEXs can potently carry HCC antigens, trigger a strong DC‐mediated immune response, and improve the HCC tumor microenvironment. (H epatology 2016;64:456‐472)

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.28549

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 · DOI
  2. 2012, Treatment of hepatocellular carcinoma: a systematic review, Liver Cancer, 1, 144, 10.1159/000343828 · DOI
  3. 2005, Vaccination of advanced hepatocellular carcinoma patients with tumor lysate‐pulsed dendritic cells: a clinical trial, J Immunother, 28, 496, 10.1097/01.cji.0000171291.72039.e2 · DOI
  4. 2015, New molecularly targeted therapies against advanced hepatocellular carcinoma: from molecular pathogenesis to clinical trials and future directions, Hepatol Res, 45, E1
  5. 2009, A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma, Hepatology, 49, 124, 10.1002/hep.22626 · DOI
  6. 2012, Classification, functions, and clinical relevance of extracellular vesicles, Pharmacol Rev, 64, 676, 10.1124/pr.112.005983 · DOI
  7. 2013, Extracellular vesicles: biology and emerging therapeutic opportunities, Nat Rev Drug Discov, 12, 347, 10.1038/nrd3978 · DOI · Paper page
  8. 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat Biotechnol, 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  9. 2014, Dendritic cell–derived exosomes as immunotherapies in the fight against cancer, J Immunol, 193, 1006, 10.4049/jimmunol.1400703 · DOI
  10. 2001, Tumor‐derived exosomes are a source of shared tumor rejection antigens for CTL cross‐priming, Nat Med, 7, 297, 10.1038/85438 · DOI
  11. 2011, Exosome‐loaded dendritic cells elicit tumor‐specific CD8+ cytotoxic T cells in patients with glioma, J Neurooncol, 104, 659, 10.1007/s11060-011-0537-1 · DOI
  12. 2013, Tumor cell‐derived exosome‐targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities, Biochem Biophys Res Commun, 436, 60, 10.1016/j.bbrc.2013.05.058 · DOI
  13. 2015, Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice, Int J Cancer, 136, E74
  14. 2013, Tumour‐derived exosomes as antigen delivery carriers in dendritic cell–based immunotherapy for malignant mesothelioma, J Extracell Vesicles, 2
  15. 1997, Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules, J Immunol, 158, 2723, 10.4049/jimmunol.158.6.2723 · DOI · Paper page
  16. 2013, Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing, Oncogenesis, 2, e44, 10.1038/oncsis.2013.8 · DOI
  17. 2009, IL‐27 directly restrains lung tumorigenicity by suppressing cyclooxygenase‐2‐mediated activities, J Immunol, 183, 6217, 10.4049/jimmunol.0901272 · DOI
  18. 2005, In vitro endothelial cell susceptibility to xenobiotics: comparison of three cell types, Cell Biol Toxicol, 21, 127, 10.1007/s10565-005-0172-8 · DOI
  19. 1980, Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen, Science, 209, 497, 10.1126/science.6248960 · DOI
  20. 1996, Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues, Int J Cancer, 66, 239, 10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7 · DOI
  21. 2007, Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester, Nat Protoc, 2, 2049, 10.1038/nprot.2007.296 · DOI
  22. 2009, Isolation of murine intrahepatic immune cells employing a modified procedure for mechanical disruption and functional characterization of the B, T and natural killer T cells obtained, Clin Exp Immunol, 155, 320, 10.1111/j.1365-2249.2008.03815.x · DOI
  23. 2008, Alpha‐fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies, Int J Infect Dis, 12, e71, 10.1016/j.ijid.2008.04.010 · DOI
  24. 2009, Glypican‐3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer, Int J Oncol, 34, 649
  25. 2012, Heat‐shock proteins as endogenous ligands building a bridge between innate and adaptive immunity, Immunotherapy, 4, 841, 10.2217/imt.12.75 · DOI
  26. 1997, Immunotherapy of tumors with autologous tumor‐derived heat shock protein preparations, Science, 278, 117, 10.1126/science.278.5335.117 · DOI
  27. 2007, Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity, Cell Mol Immunol, 4, 105
  28. 2012, Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities, Oncoimmunology, 1, 48, 10.4161/onci.1.1.18344 · DOI
  29. 1996, A direct role for IFN‐gamma in regulation of Th1 cell development, J Immunol, 157, 1350, 10.4049/jimmunol.157.4.1350 · DOI
  30. 2012, Immune microenvironment in tumor progression: characteristics and challenges for therapy, J Oncol, 2012, 608406
  31. 1980, Development of thymus, parathyroids, and ultimo‐branchial bodies in NMRI and nude mice, Am J Anat, 157, 227, 10.1002/aja.1001570303 · DOI
  32. 2014, Harnessing the exosome‐induced immune response for cancer immunotherapy, Semin Cancer Biol, 28, 58, 10.1016/j.semcancer.2014.05.003 · DOI · Paper page
  33. 2015, The yin and yang of evasion and immune activation in HCC, J Hepatol, 62, 1420, 10.1016/j.jhep.2015.02.038 · DOI
  34. 2006, A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha‐fetoprotein peptides, Clin Cancer Res, 12, 2817, 10.1158/1078-0432.CCR-05-2856 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rao, Q., Zuo, B., Lu, Z., Gao, X., You, A., Wu, C., Du, Z., & Yin, H.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-04-15
Volume
64
Issue
2
Pages
456-472
ISSN
  • 0270-9139
  • 1527-3350
DOI
10.1002/hep.28549
Cited by
246
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review